title: [Understanding current therapies in metastatic melanoma].
abstract: Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-L1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PD-L1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.
authors.affiliation: Unidad de Melanoma y Cáncer de Piel UC, Departamento de Anatomía Patológica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Rocío
authors.initials: R
authors.lastname: Rodríguez
authors.affiliation: Unidad de Melanoma y Cáncer de Piel UC, Departamento de Anatomía Patológica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Angela
authors.initials: A
authors.lastname: Parra
authors.affiliation: Unidad de Melanoma y Cáncer de Piel UC, Departamento de Anatomía Patológica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Sergio
authors.initials: S
authors.lastname: González
authors.affiliation: Unidad de Melanoma y Cáncer de Piel UC, Departamento de Anatomía Patológica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Molgó
authors.affiliation: Unidad de Melanoma y Cáncer de Piel UC, Departamento de Anatomía Patológica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Nicolás
authors.initials: N
authors.lastname: Droppelmann
authors.affiliation: Unidad de Melanoma y Cáncer de Piel UC, Departamento de Anatomía Patológica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Francisco
authors.initials: F
authors.lastname: Acevedo
authors.affiliation: Unidad de Melanoma y Cáncer de Piel UC, Departamento de Anatomía Patológica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: José
authors.initials: J
authors.lastname: Peña
authors.affiliation: Unidad de Melanoma y Cáncer de Piel UC, Departamento de Anatomía Patológica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Pablo
authors.initials: P
authors.lastname: Uribe
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary*; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors; D058990:Molecular Targeted Therapy; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020929:Mitogen-Activated Protein Kinase Kinases